Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Theravance Biopharma To Sell TRELEGY ELLIPTA Royalty Interests To Royalty Pharma for ~$1.1B In Upfront Cash With Over $1.5B In Potential Total Value

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV
byBenzinga Newsdesk
July 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1
  • Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties
  • Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm IST
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

MEI Expects Q2 Net Sales $285M-$295M Vs $310.52M Est, Adj EPS $0.12-$0.17 Vs $0.49 Est , FY24 Net Sales $1.14B-$1.18B (Prior $1.15B-$1.20B) Vs $1.16B Est, Adj EPS $0.88-$1.08 (Prior $1.55-$1.75) Vs $1.59 Est, FY25 Net Sales $1.25B-$1.35B Vs $1.25B Est

By Benzinga Newsdesk
September 7, 7:17 AM
For fiscal 2024 second quarter, the company expects net sales to be in a range of $285 to $295 million and diluted earnings per share to be in a range of $0.08 to $0.13. The

MEI